Cytokinetics (CYTK) Interest Coverage Ratio (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Interest Coverage Ratio of 115.85 for Q1 2026, down 618.1% year-over-year from 22.36 in Q1 2025, and down 256.2% quarter-over-quarter from 74.16 in Q4 2025.
Cytokinetics (CYTK) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Interest Coverage Ratio for 16 consecutive years, with 115.85 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 618.1% year-over-year to 115.85; the TTM figure through Mar 2026 stood at 32.16 (down 132.08% YoY), while the FY2025 annual figure was 2.0, down 166.52% from the prior year.
- Interest Coverage Ratio eased to 115.85 in Q1 2026 per CYTK's latest filing, from 74.16 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 74.16 in Q4 2025 and bottomed at 115.85 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 12.34 across 5 years, with a median of 12.37 in 2024.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio sank 1275.97% — and 2025, when it jumped 607.75%.
- Cytokinetics' Interest Coverage Ratio stood at 9.17 in 2022, then soared by 228.16% to 11.75 in 2023, then sank by 224.34% to 14.61 in 2024, then surged by 607.75% to 74.16 in 2025, then plunged by 256.2% to 115.85 in 2026.
- Business Quant data shows CYTK's Interest Coverage Ratio at 115.85 in Q1 2026, 74.16 in Q4 2025, and 7.53 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | -43.97 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.97 |
| Mar 31, 2026 | -115.85 |
| Dec 31, 2025 | 74.16 |
| Sep 30, 2025 | -7.53 |
| Jun 30, 2025 | -10.06 |
| Mar 31, 2025 | -16.13 |
| Dec 31, 2024 | -14.61 |
| Sep 30, 2024 | -15.77 |
| Jun 30, 2024 | -10.22 |
| Mar 31, 2024 | -12.37 |
| Dec 31, 2023 | 11.75 |
| Sep 30, 2023 | -17.13 |
| Jun 30, 2023 | -17.32 |
| Mar 31, 2023 | -17.88 |
| Dec 31, 2022 | -9.17 |
| Sep 30, 2022 | -15.94 |
| Jun 30, 2022 | -3.87 |
| Mar 31, 2022 | -11.86 |
| Dec 31, 2021 | -4.55 |
| Sep 30, 2021 | -1.57 |